Atherogenic Dyslipidemias: Unmet Needs and the Therapeutic Potential of Emerging and Novel Approaches and Drugs-Reference-Cited by-同舟云学术

Atherogenic Dyslipidemias: Unmet Needs and the Therapeutic Potential of Emerging and Novel Approaches and Drugs

Published:2023-01-24 Issue:2 Volume:16 Page:176
ISSN:1424-8247
Container-title:Pharmaceuticals
language:en
Short-container-title:Pharmaceuticals

Author:

Romandini Alessandra¹^ORCID,Baldassarre Damiano¹²^ORCID,Genovese Stefano¹,Capri Stefano³,Pompilio Giulio¹⁴,Scatigna Marco¹⁵,Werba José Pablo¹

Affiliation:

1. Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy

2. Department of Medical Biotechnology and Translational Medicine, University of Milan, 20133 Milan, Italy

3. School of Economics and Management, Cattaneo-LIUC University, 21053 Castellanza, Varese, Italy

4. Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy

5. Post-Graduate School of Clinical Pharmacology and Toxicology, University of Milan, 20133 Milan, Italy

Abstract

Innovative lipid-modifying agents are valuable resources to improve the control of atherogenic dyslipidemias and reduce the lipid-related residual cardiovascular risk of patients with intolerance or who are not fully responsive to a consolidated standard of care (statins plus ezetimibe). Moreover, some of the upcoming compounds potently affect lipid targets that are thus far considered “unmodifiable”. The present paper is a viewpoint aimed at presenting the incremental metabolic and cardiovascular benefits of the emerging lipid-modulating agents and real-life barriers, hindering their prescription by physicians and their assumption by patients, which need to be worked out for a more diffuse and appropriate drug utilization.

Funder

Italian Ministry of Health, Ricerca Corrente to Centro Cardiologico Monzino, IRCCS

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://www.mdpi.com/1424-8247/16/2/176/pdf

Reference117 articles.

1. (2023, January 14). Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes), Available online: https://clinicaltrials.gov/ct2/show/NCT02993406.

2. Cardiovascular Safety and Efficacy of the PCSK9 Inhibitor Evolocumab in Patients with and without Diabetes and the Effect of Evolocumab on Glycaemia and Risk of New-Onset Diabetes: A Prespecified Analysis of the FOURIER Randomised Controlled Trial;Sabatine;Lancet Diabetes Endocrinol.,2017

3. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome;Schwartz;N. Engl. J. Med.,2018

4. (2023, January 14). A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION-4), Available online: https://clinicaltrials.gov/ct2/show/NCT03705234.

5. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia;Bhatt;N. Engl. J. Med.,2019